Arcus Biosciences Inc (NYSE:RCUS)
$ 15.27 -0.56 (-3.54%) Market Cap: 1.40 Bil Enterprise Value: 417.63 Mil PE Ratio: 0 PB Ratio: 2.47 GF Score: 79/100

Q4 2023 Arcus Biosciences Inc Earnings Call Transcript

Feb 21, 2024 / 10:00PM GMT
Release Date Price: $16.41 (-1.14%)
Operator

Hello, and welcome to the Arcus Biosciences' full year/Q4 2023 earnings call. My name is Elliott, and I'll be coordinating your call today. (Operator Instructions)

I'd now like to hand over to Pia Eaves, Vice President of Investor Relations. The floor is yours.

Pia Eaves
Arcus Biosciences Inc - Vice President, Investor Relations

Hello, everyone, and thank you for joining us on today's conference call to discuss Arcus's fourth-quarter 2023 financial results and pipeline update. I'd like to remind you that on this call, management will make forward-looking statements, including statements about our cash runway and our expected clinical development, milestones, and timelines.

All statements other than historical facts reflect the current beliefs and expectations of management and involve risks and uncertainties that may cause our actual results to differ from those expressed. Those risks and uncertainties are described in our annual report on Form 10-K, which has been filed with the SEC. We strongly encourage you to review our filings.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot